NanoViricides' NV-387 Emerges as Potential Breakthrough in Combatting Measles Outbreaks

NanoViricides, Inc. (NYSE American: NNVC) has spotlighted its drug candidate NV-387 as a promising solution to the escalating measles outbreaks across the United States, Canada, the UK, and the European Union. With measles cases in the U.S. hitting a record 1,319 in 2025 and Canada reporting over 3,800 cases, the urgency for effective treatments has never been higher. The World Health Organization's report of 127,350 cases in Europe in 2024, the highest since 1997, further underscores the global challenge posed by this highly contagious disease.

NV-387, developed using NanoViricides' host-mimetic nanomedicine technology, has demonstrated both effectiveness and safety in preliminary studies, including a Phase I clinical trial with no adverse events. This positions NV-387 as a potential candidate for Orphan Drug and Fast Track designations, which could expedite its approval process and grant seven years of market exclusivity. Given the absence of approved drugs for measles and the challenges posed by vaccination hesitancy and immune dysfunction, NV-387 represents a critical advancement in addressing this public health crisis.

The significance of NV-387 extends beyond its immediate application to measles. As a broad-spectrum antiviral, it holds promise for treating a range of viral infections, including RSV, COVID-19, Long COVID, influenza, and other respiratory viruses, as well as MPOX/Smallpox infections. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, marking a pivotal step toward its potential commercialization and widespread use.

For more information on NanoViricides and its innovative approach to antiviral therapy, visit https://www.NanoViricides.com. Additional updates and news regarding NNVC can be found in the company's newsroom at https://ibn.fm/NNVC.